Senseonics Holdings, Inc. (SENS)
| Market Cap | 384.72M |
| Revenue (ttm) | 23.68M |
| Net Income (ttm) | -74.00M |
| Shares Out | 808.91M |
| EPS (ttm) | -0.11 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 6,316,729 |
| Open | 0.4836 |
| Previous Close | 0.4764 |
| Day's Range | 0.4515 - 0.4836 |
| 52-Week Range | 0.2500 - 1.4000 |
| Beta | 0.99 |
| Analysts | Strong Buy |
| Price Target | 1.70 (+257.44%) |
| Earnings Date | Aug 7, 2025 |
About SENS
Senseonics Holdings, Inc., a commercial-stage medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company’s products include Eversense, Eversense XL, Eversense E3, and Eversense 365, which are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and an app for real-time diabetes monitoring and management. It se... [Read more]
Financial Performance
In 2024, Senseonics Holdings's revenue was $22.47 million, an increase of 0.37% compared to the previous year's $22.39 million. Losses were -$78.62 million, 30.2% more than in 2023.
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for SENS stock is "Strong Buy." The 12-month stock price target is $1.7, which is an increase of 257.44% from the latest price.
News
Senseonics Holdings, Inc. to Host In-Person and Virtual Analyst Event at ADA 2025: Eversense® 365 Continuous Glucose Monitoring System for People with Diabetes
GERMANTOWN, Md., June 04, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable ...
Senseonics Holdings, Inc. Announces Closing of Public Offering, Including Exercise in Full of the Underwriters' Option to Purchase Additional Shares, and Closing of Private Placement
GERMANTOWN, Md., May 21, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable c...
Revisiting Senseonics After 4 Years: Still A Big Investment Opportunity
I share my recent interview with Senseonics CEO, Tim Goodnow and the CFO, Rick Sullivan. Senseonics has recently introduced a 365-day Continuous Glucose Monitoring system, aiming to disrupt a market d...
Senseonics Announces Pricing of $50 Million Public Offering of Common Stock and Concurrent Private Placement
GERMANTOWN, Md., May 15, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable c...
Senseonics Announces Commencement of $50 Million Public Offering of Common Stock and Concurrent Private Placement
GERMANTOWN, Md., May 15, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable c...
Senseonics Holdings, Inc. (SENS) Q1 2025 Earnings Call Transcript
Senseonics Holdings, Inc. (NYSE:SENS) Q1 2025 Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants Jeremy Feffer - Investor Relations, LifeSci Advisors Tim Goodnow - President and Chi...
Senseonics Holdings, Inc. Schedules First Quarter 2025 Earnings Release and Conference Call for May 8, 2025 at 4:30 P.M. Eastern Time
GERMANTOWN, Md., April 29, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable...
Sequel Med Tech and Senseonics Integrate Technologies to Create First Automated Insulin Delivery (AID) System with One-Year Continuous Glucose Monitor (CGM)
twiist™ expands compatibility offerings to become the first AID system compatible with Senseonics Eversense® 365 one-year CGM system
Senseonics Holdings, Inc. (SENS) Q4 2024 Earnings Call Transcript
Senseonics Holdings, Inc. (NYSE:SENS) Q4 2024 Earnings Conference Call March 3, 2025 4:30 PM ET Company Participants Jeremy Feffer - Investor Relations, LifeSci Advisors Tim Goodnow - President and C...
Senseonics Holdings, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results
Received FDA approval for Eversense ® 365 Continuous Glucose Monitoring system and launched Eversense 365 with commercial partner, Ascensia
Eversense 365 and SweetSpot Integrate Software to Optimize Diabetes Care
Senseonics and Ascensia integrate software between SweetSpot and Eversense 365, the world's first and only One Year CGM system
Senseonics Holdings, Inc. to Participate in the TD Cowen 45th Annual Health Care Conference
GERMANTOWN, Md., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable ...
Senseonics Completes CE Mark Submission for Eversense 365, World's Longest-lasting Continuous Glucose Monitor
GERMANTOWN, Md., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS) a medical technology company focused on the development and manufacturing of long-term, implantable c...
Senseonics Holdings, Inc. Announces Business Updates Including Preliminary 2024 Results, 365 Launch Update and Cancellation of Special Meeting
GERMANTOWN, Md., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable ...
Senseonics Holdings, Inc. (SENS) Q3 2024 Earnings Call Transcript
Senseonics Holdings, Inc. (NYSE:SENS) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Jeremy Feffer - LifeSci Advisors Tim Goodnow - President and Chief Executive Of...
Senseonics to Host Virtual KOL Event on Eversense 365: FDA Clearance and Commercialization Plans for the World's First One-Year CGM System
Event featuring David T. Ahn, MD from Hoag Medical Group and Jeff Ciaramita, MD from Mercy health system, along with management Event featuring David T. Ahn, MD from Hoag Medical Group and Jeff Ciaram...
Mercy Places First Commercial Eversense 365: The World's First and Only 365-Day Continuous Glucose Monitor
Senseonics' Eversense 365 is approved in the US as an integrated continuous glucose monitoring (iCGM) system for people with Type 1 and Type 2 diabetes aged 18 and older Commercial launch by Ascensia ...
Eversense 365 Launches in the US: One Year. One CGM.
PARSIPPANY, N.J.--(BUSINESS WIRE)--Ascensia Diabetes Care, a global diabetes care company, announces that it is launching the Eversense® 365 continuous glucose monitoring (CGM) system, the world's onl...
Eversense 365 Receives FDA Clearance: The World's First One Year CGM
GERMANTOWN, Md. & PARSIPPANY, N.J.--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantabl...
Senseonics Holdings, Inc. to Participate in the Upcoming H.C. Wainwright 26th Annual Global Investment Conference
GERMANTOWN, Md., Sept. 06, 2024 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable...
Senseonics Holdings, Inc. (SENS) Q2 2024 Earnings Call Transcript
Senseonics Holdings, Inc. (NYSE:SENS) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Company Participants Philip Taylor - Gilmartin Group, IR Tim Goodnow - President and CEO Rick Sullivan...
Senseonics Holdings, Inc. Reports Second Quarter 2024 Financial Results
GERMANTOWN, Md.--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucos...
Senseonics Holdings, Inc. Schedules Second Quarter 2024 Earnings Release and Conference Call for August 8, 2024 at 4:30 P.M. Eastern Time
GERMANTOWN, Md.--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucos...
Senseonics Holdings, Inc. Provides Business Update and Full Year 2024 Financial Outlook
GERMANTOWN, Md.--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucos...
Senseonics Holdings, Inc. to Host Business Update and Analyst Event During the American Diabetes Association's 84th Scientific Sessions
GERMANTOWN, Md.--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucos...